A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, Dipersio JF, Vij R.
Martin MG, et al. Among authors: westervelt p.
Am J Hematol. 2009 Sep;84(9):560-4. doi: 10.1002/ajh.21482.
Am J Hematol. 2009.
PMID: 19650118
Free article.
Clinical Trial.